MUMBAI, INDIA & NAPLES, USA | March 25, 2026
Lupin Limited, a global pharmaceutical leader, has received tentative approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Pitolisant Tablets (4.45 mg and 17.8 mg). This milestone marks a significant step in Lupin’s expansion of its central nervous system (CNS) portfolio and strengthens its position in the U.S. generics market. The approved product is bioequivalent to Wakix®, a therapy indicated for conditions such as narcolepsy, highlighting Lupin’s continued focus on delivering high-quality, affordable generic medicines.
Regulatory Milestone Strengthens U.S. Market Presence
The tentative FDA approval indicates that Lupin’s Pitolisant Tablets meet all quality, safety, and efficacy requirements, but final commercialization is subject to existing patent protections or exclusivity periods. This approval pathway underscores the importance of the ANDA process, which enables pharmaceutical companies to bring cost-effective alternatives to branded therapies once exclusivity expires. The product will be manufactured at Lupin’s state-of-the-art Nagpur facility in India, demonstrating the company’s robust global manufacturing capabilities and compliance with U.S. regulatory standards. This development reinforces Lupin’s strategy to expand its high-value generic portfolio in regulated markets.
Expanding CNS Portfolio with Complex Generics
Pitolisant is a histamine H3 receptor antagonist/inverse agonist, a novel mechanism of action that promotes wakefulness and cognitive function in patients with sleep disorders such as narcolepsy. By developing a generic version of Wakix®, Lupin is entering a specialized CNS therapeutic segment, which is characterized by complex formulations and stringent regulatory requirements.
Advertisement
The company’s focus on complex generics and differentiated products aligns with industry trends aimed at addressing unmet medical needs while improving accessibility and affordability. This addition to Lupin’s pipeline further enhances its capabilities in neurology and specialty pharmaceuticals, areas of growing demand globally.
Leveraging Global Manufacturing and R&D Strength
Lupin continues to leverage its extensive global footprint, with 15 manufacturing facilities and 7 research centers worldwide, to drive innovation and regulatory success. With operations spanning over 100 markets, the company has established a strong presence in key therapeutic areas including respiratory, cardiovascular, anti-diabetic, gastrointestinal, and CNS disorders. The Nagpur facility, where Pitolisant Tablets will be produced, reflects Lupin’s commitment to maintaining high-quality manufacturing standards and regulatory compliance under cGMP guidelines. Additionally, Lupin’s integrated approach—combining research, development, manufacturing, and commercialization—positions it as a competitive player in the global pharmaceutical landscape.
This tentative FDA approval highlights Lupin’s continued momentum in the generics space, reinforcing its commitment to expanding access to critical therapies while maintaining excellence in quality, compliance, and innovation across global markets.
Source: Lupin press release
